Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resveratrol for Exudative Age-Related Macular Degeneration (AGED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02625376
Recruitment Status : Unknown
Verified May 2016 by Poitiers University Hospital.
Recruitment status was:  Recruiting
First Posted : December 9, 2015
Last Update Posted : May 24, 2016
Sponsor:
Information provided by (Responsible Party):
Poitiers University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

Condition or disease Intervention/treatment Phase
AMD Age-related Macular Degeneration Choroidal Neovascularisation Dietary Supplement: Resvega Dietary Supplement: Trans-Resveratrol Dietary Supplement: placebo Not Applicable

Detailed Description:

Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

Comparison of incidence of choroidal neaovascularization between each study group will be performed.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 489 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.
Study Start Date : August 2015
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Resveratrol

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Trans-Resveratrol
capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
 Dietary Supplement: Trans-Resveratrol
Dietary supplementation with resveratrol 250 mg BD
Active Comparator: Resvega

capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.

two capsules daily : one in the morning and evening for 24 months

 Dietary Supplement: Resvega
Dietary supplementation with Resvega BD
Placebo Comparator: Placebo
capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
 Dietary Supplement: placebo
Dietary supplementation with a placebo BD


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months [ Time Frame: 24 months ]
    What is the influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second eye?


Secondary Outcome Measures :
  1. Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months [ Time Frame: 24 months ]
    What is the influence of the daily intake resvega on the incidence of neovascularization of the second eye?


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women aged 55 or more with unilateral exudative AMD
  • Visual acuity less or equal to 20/25 in the most affected eye

Exclusion Criteria:

  • Allergy to an investigational product
  • atrophic Age-Related Macular Degeneration or age related maculopathy
  • significant media opacities
  • Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy)
  • Recent Cataract surgery
  • Previous history of vitrectomy
  • Acute or chronic severe organ failure
  • Present participation in other clinical research study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625376


Contacts
Layout table for location contacts
Contact: Nicolas LEVEZIEL, MD, PhD +33 (0)5.49.44.41.82 nicolas.leveziel@chu-poitiers.fr

Locations
Layout table for location information
France
CHU de Poitiers - Ophtalmology Recruiting
Poitiers, France, 86000
Contact: Nicolas leveziel, MD       nicolas.leveziel@chu-poitiers.fr   
Sponsors and Collaborators
Poitiers University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Nicolas LEVEZIEL, MD, PhD Dpt of Ophthalmology, University Hospital of Poitiers, France
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Poitiers University Hospital
ClinicalTrials.gov Identifier: NCT02625376    
Other Study ID Numbers: AGED/EudraCT : 2015-001577-41
First Posted: December 9, 2015    Key Record Dates
Last Update Posted: May 24, 2016
Last Verified: May 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Choroidal Neovascularization
Neovascularization, Pathologic
Retinal Degeneration
Retinal Diseases
Eye Diseases
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
 Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents